CareDx Stock Price, News & Analysis (NASDAQ:CDNA) $9.81 +0.08 (+0.82%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$9.52▼$10.1450-Day Range$4.90▼$9.8852-Week Range$4.80▼$18.04Volume790,249 shsAverage Volume1.27 million shsMarket Capitalization$530.72 millionP/E RatioN/ADividend YieldN/APrice Target$13.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability CareDx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside40.7% Upside$13.80 Price TargetShort InterestHealthy7.53% of Float Sold ShortDividend StrengthN/ASustainability-0.66Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$19,472 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.82) to ($1.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.09 out of 5 starsMedical Sector420th out of 932 stocksMedical Laboratories Industry10th out of 20 stocks 3.3 Analyst's Opinion Consensus RatingCareDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.80, CareDx has a forecasted upside of 40.7% from its current price of $9.81.Amount of Analyst CoverageCareDx has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.53% of the float of CareDx has been sold short.Short Interest Ratio / Days to CoverCareDx has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in CareDx has recently decreased by 13.56%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCareDx does not currently pay a dividend.Dividend GrowthCareDx does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCareDx has received a 61.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "DNA sequencers", "Genomics analysis tools", and "Patient flow management systems" products. See details.Environmental SustainabilityThe Environmental Impact score for CareDx is -0.66. Previous Next 1.9 News and Social Media Coverage News SentimentCareDx has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for CareDx this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added CareDx to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CareDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,472.00 in company stock.Percentage Held by InsidersOnly 4.20% of the stock of CareDx is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CareDx are expected to grow in the coming year, from ($1.82) to ($1.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CareDx is -5.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CareDx is -5.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCareDx has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About CareDx Stock (NASDAQ:CDNA)CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Read More CDNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDNA Stock News HeadlinesDecember 8, 2023 | finance.yahoo.comHow Much Upside is Left in CareDx (CDNA)? Wall Street Analysts Think 26.72%December 3, 2023 | americanbankingnews.comBrokerages Set CareDx, Inc (NASDAQ:CDNA) PT at $13.80December 10, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 22, 2023 | finance.yahoo.comCan CareDx (CDNA) Climb 29.79% to Reach the Level Wall Street Analysts Expect?November 14, 2023 | markets.businessinsider.comHold Rating Maintained on CareDx Amidst Management Changes and Financial Performance: An AnalysisNovember 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: US Physical Therapy (USPH) and CareDx (CDNA)November 10, 2023 | msn.comStephens & Co. Upgrades Caredx (CDNA)November 10, 2023 | finance.yahoo.comCareDx, Inc (NASDAQ:CDNA) Q3 2023 Earnings Call TranscriptDecember 10, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 9, 2023 | msn.comCareDx stock climbs after Q3 beats, guidance boostNovember 9, 2023 | businesswire.com(0.43November 8, 2023 | benzinga.comCareDx: Q3 Earnings InsightsNovember 8, 2023 | finance.yahoo.comCareDx Reports Third Quarter 2023 ResultsNovember 6, 2023 | finance.yahoo.comCareDx (CDNA) Surges 16.6%: Is This an Indication of Further Gains?November 2, 2023 | finance.yahoo.comCareDx to Report Third Quarter 2023 Financial ResultsNovember 1, 2023 | finance.yahoo.comCareDx Announces CEO TransitionOctober 23, 2023 | seekingalpha.comCDNA, IDYA and INZY are among after hour moversOctober 17, 2023 | finance.yahoo.comCareDx Presents New Data at the American Society for Histocompatibility and Immunogenetics Annual MeetingOctober 11, 2023 | seekingalpha.comCareDx: Diversification Strategies Vs. Core WeaknessesOctober 4, 2023 | finance.yahoo.comCareDx Inc (1K9.BE)October 3, 2023 | finance.yahoo.comCareDx Issues Statement on Supreme Court Decision Regarding Stanford-Licensed PatentsOctober 2, 2023 | reuters.comUS Supreme Court rebuffs CareDx patent lawsuit over organ-rejection testsSeptember 27, 2023 | msn.comStephens & Co. Reiterates Caredx (CDNA) Equal-Weight RecommendationSeptember 19, 2023 | finance.yahoo.comCareDx To Present at the 2023 Cantor Global Healthcare ConferenceSeptember 14, 2023 | finance.yahoo.comCareDx Advances Global Transplant Patient Care at ESOT Congress 2023August 31, 2023 | msn.comCaredx (CDNA) Price Target Increased by 8.00% to 11.02August 31, 2023 | finance.yahoo.comCareDx To Present at the H.C. Wainwright 25th Annual Global Investment ConferenceSee More Headlines Receive CDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today12/09/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CDNA CUSIPN/A CIK1217234 Webwww.caredxinc.com Phone(415) 287-2300Fax415-287-2450Employees727Year FoundedN/APrice Target and Rating Average Stock Price Target$13.80 High Stock Price Target$25.00 Low Stock Price Target$9.00 Potential Upside/Downside+40.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,610,000.00 Net Margins-30.46% Pretax Margin-30.41% Return on Equity-21.94% Return on Assets-17.35% Debt Debt-to-Equity RatioN/A Current Ratio4.75 Quick Ratio4.50 Sales & Book Value Annual Sales$321.79 million Price / Sales1.65 Cash FlowN/A Price / Cash FlowN/A Book Value$8.05 per share Price / Book1.22Miscellaneous Outstanding Shares54,100,000Free Float51,826,000Market Cap$530.72 million OptionableOptionable Beta1.36 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Abhishek Jain (Age 46)CFO & Principal Accounting Officer Comp: $425.58kDr. Peter Maag Ph.D. (Age 56)Executive Director Comp: $43.23kMr. Alexander L. Johnson (Age 49)President of Patient & Testing Services Comp: $547.43kMs. Marica Grskovic Ph.D.Chief Operating OfficerDr. Robert N. Woodward Ph.D.Chief Scientific OfficerMr. GS JhaSenior VP, Chief Information Officer & Chief Information Security OfficerMr. Ian CooneyVice President of Investor RelationsDr. Mickey Y. Kim M.D.Senior VP of Corporate Development & Head of Global ProductMr. Jarrod BorkatSenior VP and Head of Marketing & Portfolio OperationsMs. Stacey FollonSenior VP & Head of Human ResourcesMore ExecutivesKey CompetitorsCastle BiosciencesNASDAQ:CSTLCelcuityNASDAQ:CELCFulgent GeneticsNASDAQ:FLGTInvitaeNYSE:NVTAHH&L AcquisitionNYSE:HHLAView All CompetitorsInsiders & InstitutionsCitigroup Inc.Bought 8,768 shares on 12/6/2023Ownership: 0.245%American Century Companies Inc.Bought 9,160 shares on 11/30/2023Ownership: 0.063%Deutsche Bank AGSold 288,740 shares on 11/24/2023Ownership: 0.047%Walleye Capital LLCSold 68,809 shares on 11/21/2023Ownership: 0.478%Jacobs Levy Equity Management Inc.Bought 432,090 shares on 11/17/2023Ownership: 2.078%View All Insider TransactionsView All Institutional Transactions CDNA Stock Analysis - Frequently Asked Questions Should I buy or sell CareDx stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CDNA shares. View CDNA analyst ratings or view top-rated stocks. What is CareDx's stock price target for 2024? 6 brokers have issued 12 month price targets for CareDx's shares. Their CDNA share price targets range from $9.00 to $25.00. On average, they predict the company's stock price to reach $13.80 in the next year. This suggests a possible upside of 40.7% from the stock's current price. View analysts price targets for CDNA or view top-rated stocks among Wall Street analysts. How have CDNA shares performed in 2023? CareDx's stock was trading at $11.41 at the start of the year. Since then, CDNA stock has decreased by 14.0% and is now trading at $9.81. View the best growth stocks for 2023 here. Are investors shorting CareDx? CareDx saw a decline in short interest in November. As of November 15th, there was short interest totaling 3,890,000 shares, a decline of 13.6% from the October 31st total of 4,500,000 shares. Based on an average daily trading volume, of 957,600 shares, the short-interest ratio is currently 4.1 days. Currently, 7.5% of the shares of the company are sold short. View CareDx's Short Interest. When is CareDx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our CDNA earnings forecast. How were CareDx's earnings last quarter? CareDx, Inc (NASDAQ:CDNA) issued its quarterly earnings results on Wednesday, November, 8th. The company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by $0.06. The business had revenue of $67.19 million for the quarter, compared to analysts' expectations of $53.14 million. CareDx had a negative trailing twelve-month return on equity of 21.94% and a negative net margin of 30.46%. The firm's revenue was down 15.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.32) EPS. What ETFs hold CareDx's stock? ETFs with the largest weight of CareDx (NASDAQ:CDNA) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Jacob Forward ETF (JFWD), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and Global X Genomics & Biotechnology ETF (GNOM).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG). What guidance has CareDx issued on next quarter's earnings? CareDx updated its FY 2023 earnings guidance on Wednesday, November, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $274.00 million-$278.00 million, compared to the consensus revenue estimate of $255.42 million. What other stocks do shareholders of CareDx own? Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Block (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA). Who are CareDx's major shareholders? CareDx's stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (12.33%), Sumitomo Mitsui Trust Holdings Inc. (5.58%), Armistice Capital LLC (3.76%), Kent Lake Capital LLC (2.54%), Jacobs Levy Equity Management Inc. (2.08%) and First Eagle Investment Management LLC (1.86%). Insiders that own company stock include Ankur Dhingra, George Bickerstaff, Grace Colon, Michael Goldberg, Paul Adler, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, Thomas A Thomas and William A Hagstrom. View institutional ownership trends. How do I buy shares of CareDx? Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CDNA) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CareDx, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.